Indeed, a small-molecule compound that inhibits WRN helicase activity, obtained by screening, sensitizes cancer cells to some DNA-damaging agents, including topoisomerase inhibitors, poly(ADP ribose) polymerase (PARP) inhibitors, and DNA cross-linking agents [68,69], as well as BRCA2-mutated cells [70]. Here, WRN is linked to cancer.